The advent of Next Generation Sequencing (NGS) technologies has provided researchers with an unparalleled opportunity for the identification of novel therapeutic targets for drug discovery and development. We apply and develop quantitative tools for target identification and validation resulting from the association of genomic structural variation (‘omics) data with clinical data. Our research expertise involves managing large scale and complex family/population-based GWAS, NGS and phenotype data such as electronic medical records, longitudinal outcomes, etc.